Anna Protopapas is a veteran biotech executive with a substantial track record of leadership and business experience in oncology. Her broad industry experience ranges from global development to commercial expertise with a focus on building businesses from start-ups to leaders in their categories to deliver meaningful therapies to patients. She joined Nuvalent as Board Chair in March 2022.
Ms. Protopapas is President and Chief Executive Officer of Mersana Therapeutics, a clinical-stage biopharmaceutical company developing novel ADCs against cancer.
Prior to Mersana, Ms. Protopapas was President of Millennium Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, where she led Takeda’s oncology business. Ms. Protopapas also served as Executive Vice President of Global Business Development at Takeda, was a member of the company’s executive committee, and served as a corporate officer. Earlier, Ms. Protopapas was an executive officer at Millennium and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader.
This person is not in the org chart
This person is not in any teams
Nuvalent
1 followers
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.